1 Fisher M, Schaebitz W. An Overview of acute stroke

therapy: past, present and future[J]. Arch Intern Med,

2000, 160:3196-3206.

2 Mau r iel lo A, Sangiorgi G, Palmier i G, et al.

Hyperfibrinogenemia is associated with specific

histocytological composition and complications of

atherosclerotic carotid plaques in patients affected

by transient ischemic attacks[J]. Circulation, 2000,

101:744-750.

3 Eidelman RS, Hennekens CH. Fibrinogen: a predictor

of stroke and marker of atherosclerosis[J]. J Eur Heart,

2003, 24:499-500.

4 Ross R. Atherosclerosis: an inflammatory disease[J].

N Engl J Med, 1999, 340:115-126.

5 Sabeti S, Exner M, Mlekusch W, et al. Prognostic

impact of f ibrinogen in carotid atherosclerosis

nonspecific indicator of inflammation or independent

predictor of disease progression?[J]. Stroke, 2005,

36:1400-1404.

6 Sans E, Delachanal E, Duperray A. Analysis of the

roles of ICAM-1 in neutrophil transmigration using

a reconstituted mammalian cell expression model:

Implication of ICAM-1 cytoplasmic domain and Rhodependent

signaling pathway[J]. J Immunol, 2001,

166:544-551.

7 Bobr yshev YV, Che r ian SM, I nde r SJ, et a l.

Neovascular expression of VE-cadherin in human

atherosclerotic arteries and its relation to intimal

inflammation[J]. Cardiovasc Res, 1999, 43:1003-1017.

8 王引明, 曹勇军, 刘春风, 等. 抗血小板药物对脑梗死

患者血小板-白细胞聚集体的影响[J]. 中华内科杂志,

2007, 46:562-565.

9 Cao YJ, Wang YM, Zhang J, et al. The effects of

antiplatelet agents on platelet-leukocyte aggregations

in patients with acute cerebral infarction[J]. J Thromb

Thrombolysis, 2009, 27:233-238.

10 曹勇军, 吴延华, 刘春风.纤维蛋白原、纤维蛋白及其

降解产物对共培养血管内皮细胞纤溶活性的影响[J].

中华心血管病杂志, 2008, 36:62-67.

11 钱进军, 刘春风,赵康仁. 脑梗死患者β纤维蛋白

原-455G/A和-148C/T基因多态性研究[J]. 中华神经科

杂志, 2004, 37:90-92.

12 Tataru MC, Schulte H, von Eckardstein A, et al.

Plasma fibrinogen in relation to the severity of

arteriosclerosis in patients with stable angina pectoris

after myocardial infarction[J]. Coron Artery Dis,

2001, 12:157-165.

13 Bots ML, Elwood PC, Salonen JT, et al. Level of

fibrinogen and risk of fatal and non-fatal stroke

EUROSTROKE: a collaborative study among research

centres in Europe[J]. J Epidemiol Community Health,

2002, 56:i14-i18.

14 Fibr inogen St udie s Col labor at ion, Dane sh J,

Lewington S, et al. Plasma fibrinogen level and the

risk of major cardiovascular diseases and nonvascular

mortality:an individual participant Meta-analysis[J].

JAMA, 2005, 294:1799-1809.

15 高晶, 刘秀琴, 郭玉璞. 降纤制剂的研究和临床应用新

进展[J]. 中华神经科杂志, 2001, 4:305-307.

16 Wang F, Wang C, Li M, et al. Crystal structure of

earthworm fibrinolytic enzyme component A:a novel,

glycosylated two-chained trypsin[J]. J Mol Biol, 2005,

348:671-685.

17 She rma n DG, At k i n son RP, Ch ip p e nd a l e T.

Intravenous ancrod for treatment of acute ischemic

stroke: the STAT study: a randomized controlled trial.

Stroke Treatment with Ancrod Trial[J]. JAMA, 2000,

283:2395-2403.

18 The Ancrod Stroke Study Investigators. Ancrod for

the treatment of acute ischemic brain infarction[J].

Stroke, 1994, 25:1755-1759.

19 Hennerici MG, Kay R, Bogousslavsky J, et al.

Intravenous ancrod for acute ischaemic stroke in

the European stroke treatment with Ancrod Trial:

a randomised controlled trial[J]. Lancet, 2006,

368:1871-1878.

20 全国降纤酶临床再评价研究协作组. 降纤酶治疗急

性脑梗死的临床再评价[J]. 中华神经科杂志, 2000,

33:263-267.

21 全国降纤酶临床再评价研究协作组. 降纤酶治疗急

性脑梗死临床再评价(Ⅱ)[J]. 中华神经科杂志, 2005,

38:11-16.

22 Liu M, Counsell C, Zhao XL, et al. Fibrinogen

depleting agents for acute ischemic stroke[M].

Cochrane Database Syst Rev, 2003, (3):CD000091.

23 饶明利, 主编. 中国脑血管病防治指南[M]. 北京: 人民

卫生出版社, 2007:34-35.

24 Ad ams HP, del Zoppo G, Albe r t s MJ, e t a l .

Guidelines for the early management of adults with

ischemic stroke. a guideline from the American

Heart Association/American Stroke Association

St roke Council, Clinical Ca rdiology Council,

Cardiovascular Radiology and Intervention Council,

and the Athe roscle rot ic Pe r iphe r a l Va scula r

Disease and Quality of Care Outcomes in Research

Interdisciplinary Working Groups: the American

Academy of Neurology affirms the value of this

guideline as an educational tool for neurologists[J].

Stroke, 2007, 38:1655-1711.